Who owns RARE?
Institutional ownership of Ultragenyx Pharmaceutical Inc. from Form 13F, Q2 2026
310 institutional managers reported holding Ultragenyx Pharmaceutical Inc. (RARE) in Form 13F filings for Q2 2026, with 106,897,175 shares worth $3.6B. The largest reported holder was BlackRock, Inc. Managers that filed both quarters added a net 8,799,085 shares (+9.0%). 56 opened new positions and 42 sold out.
- Funds holding
- 310
- Value held
- $3.6B
- New / sold out
- 56 / 42
- Net shares, same filers
- +9.0%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of RARE
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| BlackRock, Inc. | $356M | 10.0% | 10,654,276 | Added |
| RTW Investments, LP | $260M | 7.3% | 7,796,895 | Added |
| Vanguard Portfolio Management LLC | $227M | 6.4% | 6,790,135 | Added |
| AQR Capital Management LLC | $214M | 6.1% | 6,560,809 | Added |
| State Street Corp | $206M | 5.8% | 6,158,766 | Added |
| Vanguard Capital Management LLC | $143M | 4.0% | 4,296,491 | Added |
| Two Sigma Investments, LP | $121M | 3.4% | 3,621,200 | Added |
| Sands Capital Management, LLC | $105M | 3.0% | 3,158,368 | Trimmed |
| Jacobs Levy Equity Management, Inc | $98.2M | 2.8% | 2,939,719 | Added |
| Frontier Capital Management Co LLC | $95.1M | 2.7% | 2,847,936 | Added |
| Geode Capital Management, LLC | $86.1M | 2.4% | 2,578,828 | Added |
| Bellevue Group AG | $66.2M | 1.9% | 1,982,775 | Trimmed |
| D. E. Shaw & Co., Inc. | $57.8M | 1.6% | 1,730,193 | Added |
| Sofinnova Investments, Inc. | $57.3M | 1.6% | 1,717,505 | Trimmed |
| Adage Capital Partners GP, L.l.c. | $52.8M | 1.5% | 1,580,000 | Added |
| GW&K Investment Management, LLC | $49.5M | 1.4% | 1,481,178 | Trimmed |
| MPM Bioimpact LLC | $47.4M | 1.3% | 1,418,215 | New |
| Price T Rowe Associates Inc | $45.3M | 1.3% | 1,356,501 | Added |
| Morgan Stanley | $44.2M | 1.2% | 1,324,805 | Trimmed |
| Wellington Management Group LLP | $41.8M | 1.2% | 1,250,464 | Trimmed |
| Voloridge Investment Management, LLC | $41.5M | 1.2% | 1,241,556 | Trimmed |
| Bank of America Corp | $38.3M | 1.1% | 1,148,454 | Added |
| Candriam S.C.A. | $33.4M | 0.9% | 1,001,841 | Trimmed |
| Rock Springs Capital Management LP | $32.3M | 0.9% | 967,855 | Trimmed |
| Jefferies Financial Group Inc. | $31.0M | 0.9% | 929,626 | Added |
Share of 13F holdings is each fund's shares as a share of the 106,897,175 RARE shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- RTW Investments, LP Added+$139M
- BlackRock, Inc. Added+$112M
- AQR Capital Management LLC Added+$64.7M
- Jacobs Levy Equity Management, Inc Added+$50.4M
- MPM Bioimpact LLC New+$47.4M
- Two Sigma Investments, LP Added+$47.3M
- Vanguard Portfolio Management LLC Added+$46.9M
- State Street Corp Added+$38.0M
- Adage Capital Partners GP, L.l.c. Added+$36.7M
- Jefferies Financial Group Inc. Added+$30.5M
Biggest sellers in Q2 2026
- Assenagon Asset Management S.A. Trimmed-$67.3M
- Citadel Advisors LLC Trimmed-$63.6M
- Sofinnova Investments, Inc. Trimmed-$47.7M
- Wellington Management Group LLP Trimmed-$46.4M
- Millennium Management LLC Trimmed-$33.8M
- Jones Hill Capital LP Sold out-$24.4M
- Point72 Asset Management, L.P. Sold out-$18.7M
- Catalio Capital Management, LP Trimmed-$17.8M
- Schonfeld Strategic Advisors LLC Trimmed-$14.8M
- Bellevue Group AG Trimmed-$13.3M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $916M and sold $565M; 115 added and 97 trimmed.
Schedule 13D and 13G filings on RARE
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-11-10STATE STREET CORP SCHEDULE 13G filed by Ultragenyx Pharmaceutical Inc.Schedule 13G
- 2026-08-14RTW INVESTMENTS, LP SCHEDULE 13G filed by Ultragenyx Pharmaceutical Inc.Schedule 13G
- 2026-08-13AQR CAPITAL MANAGEMENT LLC SCHEDULE 13G filed by Ultragenyx Pharmaceutical Inc.Schedule 13G
- 2026-08-07STATE STREET CORP SCHEDULE 13G filed by Ultragenyx Pharmaceutical Inc.Schedule 13G
- 2026-05-12STATE STREET CORP SCHEDULE 13G filed by Ultragenyx Pharmaceutical Inc.Schedule 13G
- 2025-11-05FMR LLC SCHEDULE 13G filed by Ultragenyx Pharmaceutical Inc.Schedule 13G
Questions about RARE ownership
- Who owns RARE stock?
- 310 institutional investment managers reported RARE positions in their Form 13F filings for Q2 2026, holding 106,897,175 shares worth $3.6B in total. BlackRock, Inc. reported the largest position.
- Are funds buying or selling RARE?
- In Q2 2026, 56 managers opened new RARE positions, 115 added, 97 trimmed and 42 sold out. Managers that filed in both quarters added a net 8,799,085 shares.
- How current is this RARE institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to RARE by CUSIP. Options are left out. RARE news and filings · RARE insider trades · Top funds